Copper-binding tripeptide researched for skin regeneration, wound healing, collagen stimulation, and anti-aging effects.
Last Updated: May 2026
GHK-Cu is a copper-binding tripeptide (Gly-His-Lys) complexed with copper(II), researched for skin regeneration, collagen stimulation, wound healing, and broader anti-aging effects. It is one of the longest-studied peptides in cosmetic science, with both topical cosmetic and injectable research applications. Important regulatory update: Injectable GHK-Cu was removed from the FDA's Category 2 bulk substances list on April 22, 2026 and is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review in early 2027. Non-injectable GHK-Cu is on a separate evaluation path, also anticipated before February 2027.
GHK-Cu is the tripeptide Gly-His-Lys (GHK) complexed with copper(II), which dramatically increases the peptide's biological activity. The intact complex acts through multiple mechanisms: copper-dependent enzyme activation (lysyl oxidase for collagen crosslinking, superoxide dismutase for antioxidant defense), direct stimulation of dermal fibroblasts, anti-inflammatory effects, and gene expression modulation. GHK-Cu has been shown to modulate expression of over 4,000 genes in published transcriptomic studies, reflecting broad biological effects. Endogenous GHK levels in plasma decline substantially with age. Evidence level: Established cosmetic and dermatological use; preclinical extensive (collagen, wound healing, gene expression); limited human RCT for injectable use.
Topical GHK-Cu has been used in cosmetic skincare for decades with established effects on collagen synthesis, skin elasticity, and wrinkle reduction documented in cosmetic dermatology research. Injectable GHK-Cu has been studied in preclinical wound healing models with favorable results but lacks Phase 2/3 RCT-grade human evidence. The compound has been one of the most-referenced ingredients in evidence-based cosmetic science. Evidence level: Topical: established cosmetic use; injectable: preclinical extensive, limited human RCT.
GHK-Cu and AHK-Cu are the two main copper tripeptides in cosmetic and research use — GHK-Cu for general skin regeneration and collagen, AHK-Cu primarily for hair follicle stimulation. Different tripeptide sequences (Gly-His-Lys versus Ala-His-Lys) confer different tissue specificity.
| Compound | Tripeptide sequence | Primary application | Evidence stage |
|---|---|---|---|
| GHK-Cu | Gly-His-Lys + Cu²⁺ | Skin regeneration, collagen, wound healing | Established cosmetic + preclinical |
| AHK-Cu | Ala-His-Lys + Cu²⁺ | Hair follicle stimulation | Preclinical + cosmetic use |
| SNAP-8 | Synthetic octapeptide | Wrinkle reduction (botox alternative) | Cosmetic + limited clinical |
Topical GHK-Cu has an extensive cosmetic safety record with rare reports of contact dermatitis as the primary concern. Injectable use side effects in available research and community-reported use are mild — injection-site reactions, occasional transient flushing. The copper content raises theoretical concerns about copper accumulation with sustained high-dose use, though clinically meaningful copper toxicity has not been reported at researched doses. Evidence level: Extensive cosmetic safety; injectable research safety; long-term high-dose unestablished.
Topical GHK-Cu is widely incorporated into cosmetic skincare products and is not subject to specific therapeutic regulation in cosmetic-grade use. Injectable GHK-Cu is not approved for any therapeutic indication. On April 22, 2026, injectable GHK-Cu was removed from the FDA's Category 2 bulk substances list and is scheduled for PCAC review in early 2027. Non-injectable GHK-Cu is on a separate evaluation path, also anticipated before February 2027. Current status in FDA peptide regulation 2025–2026 timeline.
GHK-Cu is widely sold across cosmetic, supplement, and research-grade supply chains with substantial quality variance — and the copper-complexed form versus free GHK peptide are pharmacologically distinct. Some vendors sell free GHK labeled as GHK-Cu (mislabeling) or use suboptimal copper-to-peptide ratios. Independent HPLC and copper content verification are the meaningful quality signals. Guidance in how-to-test-peptides hub.
Peptigrity purchases GHK-Cu vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis with copper content verification, and publishes the unedited certificate of analysis. Methodology in how we calculate trust scores.
GHK-Cu stimulates collagen production, supports skin regeneration and wound healing, and produces broad anti-aging effects on skin through multiple molecular mechanisms. Topical use has extensive cosmetic evidence; injectable use is researched but lacks Phase 2/3 RCT-grade human data.
Topical GHK-Cu is widely available in cosmetic skincare products. Injectable GHK-Cu is legal to purchase as a research chemical for laboratory use in most jurisdictions but is not approved for human consumption. The April 22, 2026 Category 2 removal opens a potential future compounding pathway pending PCAC review in early 2027. Country breakdown in peptide legal status guide.
Injectable GHK-Cu is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review in early 2027, separately from the July 2026 PCAC reviewing BPC-157, TB-500, and others. Non-injectable GHK-Cu has a separate evaluation pathway also anticipated before February 2027. Track developments in FDA peptide regulation 2025–2026 timeline.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation and copper content verification. The copper-complexed form is what produces the biological activity; free GHK without copper has much weaker effects. COA interpretation in red flags in peptide certificates of analysis.
No. Peptigrity is an independent review platform, not a medical authority. Topical cosmetic dosing follows product instructions; injectable research-use dosing varies. Anyone considering injectable use should consult a licensed physician.
Topical GHK-Cu has an extensive cosmetic safety record. Injectable long-term safety at sustained research-use dosing is less characterized than cosmetic use, with theoretical concerns about copper accumulation but no clinically reported toxicity at researched doses. Anyone considering sustained injectable use should consult a licensed physician.
This section is for educational and informational purposes only and does not constitute medical advice. Topical GHK-Cu is widely available cosmetically; injectable GHK-Cu is not FDA-approved for human use, though it was removed from Category 2 of the FDA 503A bulk substances list in April 2026 and is scheduled for PCAC review in early 2027. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.